Cancer Therapeutics Market by Application (Blood Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, and Others) and Top Selling Drugs (Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023
- Published Date: 2020-10-18
- Report ID: 3040
- Pages: 226
-
Format:
The use of targeted, biologic (immunotherapy) & other forms of therapies administered to treat cancer through oncology drugs is known as cancer therapeutics. The global cancer therapeutics market was valued at $81,291 million in 2016 and is estimated to reach at $178,863 million by 2023, registering a CAGR of 11.9% from 2017 to 2023.
Upsurge in collaboration between pharmaceutical companies, rise in cancer awareness & availability of oncology drugs, increase in cancer funding & research, and growth in geriatric population are the key factors that augment the growth of the cancer therapeutics market. Furthermore, rise in prevalence of cancer cases is expected to boost the market growth.
However, adverse effects associated with cancer therapeutics market and high costs associated with oncology drug development are some of the factors that impede the market growth. Conversely, the high potential of emerging economies and increase in demand for personalized medicine is expected to provide new opportunities for the market players in future.
The cancer therapeutics market is segmented based on application, top selling drugs, and region. Based on application, the market is divided into blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, and others. By top selling drugs, it is categorized into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, and others. Region wise, it is analyzed across the North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
This report entails a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities along with strategic assessment of global cancer therapeutics market.
Cancer therapeutics market size and market estimations are based on comprehensive analysis of the applications, top selling drugs, and developments in the industry.
An in-depth analysis based on region assists to understand the regional market and facilitate the strategic business planning.
The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Application
Blood Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Breast Cancer
Cervical Cancer
Others
By Top Selling Drugs
Revlimid
Avastin
Herceptin
Rituxan
Opdivo
Gleevec
Velcade
Imbruvica
Ibrance
Zytiga
Alimta
Xtandi
Tarceva
Perjeta
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Rest of Asia-Pacific
LAMEA
Latin America
Middle-East
Africa
The list of key players operating in this market include:
F. Hoffmann-La Roche AG
Bristol-Myers Squibb Company
AbbVie, Inc.
Johnson & Johnson
Celgene Corporation
Astellas Pharma, Inc.
Pfizer, Inc.
Novartis AG
Merck KGaA
Eli Lilly and Company
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Market share analysis, 2016
3.4. Porters five forces analysis
3.5. Clinical trials
3.6. Market dynamics
3.6.1. Drivers
3.6.1.1. Increase in prevalence of cancer
3.6.1.2. Surge in cancer research
3.6.1.3. Rise in strategic acquisitions and collaborations
3.6.2. Restraints
3.6.2.1. High cost of drug development and threat of failure
3.6.2.2. Adverse effects associated with cancer drug therapy
3.6.3. Opportunities
3.6.3.1. High potential associated with personalized medicines
3.6.3.2. Increase in purchasing power of emerging economics
CHAPTER 4: CANCER THERAPEUTICS MARKET, APPLICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Blood cancer
4.2.1. Key market trends, growth factors & opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Lung cancer
4.3.1. Key market trends, growth factors & opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Breast cancer
4.4.1. Key market trends, growth factors & opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Colorectal cancer
4.5.1. Key market trends, growth factors & opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Prostate cancer
4.6.1. Key market trends, growth factors & opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country
4.7. Other cancers
4.7.1. Key market trends, growth factors & opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country
CHAPTER 5: CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS
5.1. Overview
5.1.1. Market size and forecast
5.2. Revlimid
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by region
5.3. Avastin
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by region
5.4. Herceptin
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by region
5.5. Rituxan
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by region
5.6. Opdivo
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by region
5.7. Gleevec
5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by region
5.8. Velcade
5.8.1. Market size and forecast, by region
5.8.2. Market analysis, by region
5.9. Imbruvica
5.9.1. Market size and forecast, by region
5.9.2. Market analysis, by region
5.10. Ibrance
5.10.1. Market size and forecast, by region
5.10.2. Market analysis, by region
5.11. Zytiga
5.11.1. Market size and forecast, by region
5.11.2. Market analysis, by region
5.12. Alimta
5.12.1. Market size and forecast, by region
5.12.2. Market analysis, by region
5.13. Xtandi
5.13.1. Market size and forecast, by region
5.13.2. Market analysis, by region
5.14. Tarceva
5.14.1. Market size and forecast, by region
5.14.2. Market analysis, by region
5.15. Perjeta
5.15.1. Market size and forecast, by region
5.15.2. Market analysis, by region
5.16. Other drugs
5.16.1. Market size and forecast, by region
5.16.2. Market analysis, by region
CHAPTER 6: CANCER THERAPEUTICS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America market size and forecast, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. market size and forecast, by application
6.2.2.2. Canada
6.2.2.2.1. Canada market size and forecast, by application
6.2.3. North America market size and forecast, by application
6.2.4. North America market size and forecast, by top selling drugs
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe Cancer Therapeutics market, by country
6.3.2.1. Germany
6.3.2.1.1. Germany market size and forecast, by application
6.3.2.2. France
6.3.2.2.1. France market size and forecast, by application
6.3.2.3. UK
6.3.2.3.1. UK market size and forecast, by application
6.3.2.4. Italy
6.3.2.4.1. Italy market size and forecast, by application
6.3.2.5. Spain
6.3.2.5.1. Spain market size and forecast, by application
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe market size and forecast, by application
6.3.3. Europe market size and forecast, by application
6.3.4. Europe market size and forecast, by top selling drugs
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan market size and forecast, by application
6.4.2.2. China
6.4.2.2.1. China market size and forecast, by application
6.4.2.3. India
6.4.2.3.1. India market size and forecast, by application
6.4.2.4. Rest of Asia-Pacific
6.4.2.4.1. Rest of Asia-Pacific market size and forecast, by application
6.4.3. Asia-Pacific market size and forecast, by application
6.4.4. Asia-Pacific market size and forecast, by top selling drugs
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. LAMEA market size and forecast, by country
6.5.2.1. Latin America
6.5.2.1.1. Latin America market size and forecast, by application
6.5.2.2. Middle East
6.5.2.2.1. Middle-East market size and forecast, by application
6.5.2.3. Africa
6.5.2.3.1. Africa market size and forecast, by application
6.5.3. LAMEA market size and forecast, by application
6.5.4. LAMEA market size and forecast, by top selling drugs
CHAPTER 7: COMPANY PROFILES
7.1. AbbVie Inc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Business performance
7.1.5. Key strategic moves and developments
7.2. Astellas Pharma Inc.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Business performance
7.2.5. Key strategic moves and developments
7.3. Bristol Myers Squibb Company
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Business performance
7.3.5. Key strategic moves and developments
7.4. Celgene Corporation
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Business performance
7.5. Eli Lilly and Company
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Business performance
7.5.5. Key strategic moves and developments
7.6. F. Hoffmann-La Roche Ltd.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Business performance
7.6.5. Key strategic moves and developments
7.7. Johnson & Johnson
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Business performance
7.7.5. Key strategic moves and developments
7.8. Merck & Co., Inc.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Business performance
7.8.5. Key strategic moves and developments
7.9. Novartis AG
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Business performance
7.9.5. Key strategic moves and developments
7.10. Pfizer Inc.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Business performance
7.10.5. Key strategic moves and developments
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
